Beauty Health Q2 sales miss estimates on lower delivery systems - SKIN News | Rallies
Beauty Health Q2 sales miss estimates on lower delivery systems S SKIN • 2026-08-06 Result drivers
Sales pressure - Co said lower delivery systems and consumables net sales drove the decline in Q2 revenueOperating expenses - Co said lower personnel-related expenses reduced operating and adjusted operating expensesGross margin improvement - Co attributed higher gross margin to elevated product costs and inventory charges in the prior year Outlook for 2026
Company sees Q3 2026 net sales between $65 mln and $70 mln
Company expects Q3 2026 adjusted EBITDA of $5 mln to $7 mln
Company forecasts 2026 net sales of $280 mln to $290 mln
Company expects 2026 adjusted EBITDA of $39 mln to $46 mln
Company says guidance reflects continued sales pressure and ongoing cost discipline
Q2 sales miss estimates
US medical aesthetics firm's Q2 sales fell 7.8% yr/yr, missing analyst expectations
Adjusted EBITDA for Q2 beat analyst estimates, driven by improved gross margin and lower expenses
Company attributed gross margin improvement to reduced product costs and inventory charges vs prior year
Key quarterly figures and analyst coverage Metric Beat/Miss Actual Consensus Estimate Q2 Sales Miss $72.10 mln $74.29 mln (9 Analysts) Q2 Net Loss $2.70 mln Q2 Adjusted EBITDA Beat $17 mln $11.62 mln (9 Analysts) Q2 Adjusted Gross Margin 71.80%
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 6 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the personal products peer group is "buy"
Wall Street's median 12-month price target for Skinhealth Systems Inc is $1.03, about 45.3% above its August 5 closing price of $0.71
•
2026-08-06
SKIN•
